Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients [clinicaltrials:NCT02036554]

Bio2RDF uri

Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients [clinicaltrials:NCT02036554]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02036554

Bio2RDF identifier

NCT02036554

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02036554

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02036554

acronym [clinicaltrials_vocabulary:acronym]

PROTECT

http://www.w3.org/2001/XMLSchema#string

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

234

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02036554 arm group 67b85839452365b0bba10e307655dec6 [clinicaltrials_resource:NCT02036554/arm-group/67b85839452365b0bba10e307655dec6]

NCT02036554 arm group b38071de9eaadeb278fcc2d7e1098686 [clinicaltrials_resource:NCT02036554/arm-group/b38071de9eaadeb278fcc2d7e1098686]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:f0fd3e8921a9ab139a945976a9b8d604

brief summary [clinicaltrials_vocabulary:brief-summary]

To evaluate prevention ...... he renal allograft recipients

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Evaluate Efficacy Study of Com ...... in Renal Allograft Recipients

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:70e5722d73edcff4ac7cef8d31fa06df]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:096f591b40a5618abfc5f26ae2814423]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:0c3fb15a8e98a61d6f59c18778b09965]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:14c21d653c0a3087f97b712f11acc32d]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:1b4afbbda72edf0a04ede89ee1b415b5]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:2f3f4e2e7a5e82146e92c09a5c281a3f]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:365a3fa606339eb7b1d112661d3cde66]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:3d4e1f4975b6453969a6438d3ce99f85]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:3e8ca50d241ae75969c704bf60902960]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:4768c57e6049b3f036d89f741ad29db8]

Change from Baseline in Development of NODAT (Fasting glucose ≥ 126 mg/dL, Random glucose ≥ 200 mg/dL) at 12 months 0 to 12 month [clinicaltrials_resource:4a1d3cd87633b7fbc1fb901f0c8ab404]

collaborator [clinicaltrials_vocabulary:collaborator]

Seoul St. Mary's Hospital [clinicaltrials_resource:3dd51fe21291c57b6fa19fca7c5200f8]

completion date [clinicaltrials_vocabulary:completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Kidney; Complications, Allograft [clinicaltrials_resource:caa5c38e3051f068585e33571eae0073]

country [clinicaltrials_vocabulary:country]

Korea, Republic of [clinicaltrials_resource:c3f33959145b7a47d9100055b6805510]

detailed description [clinicaltrials_vocabulary:detailed-description]

An open-label, randomiz ...... aft recipients: PROTECT study

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02036554 [clinicaltrials_resource:52f013f982f1d38b3c6cddda509ce13c]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Seoul St. Mary's Hospital [clinicaltrials_resource:3dd51fe21291c57b6fa19fca7c5200f8]

location [clinicaltrials_vocabulary:location]

division of nephrology;Seoul St Mary's Hospital [clinicaltrials_resource:7d650dc60c3cf4917c922edd81b8a2c8]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02036554

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

To Evaluate Prevention Effect ...... the Renal Allograft Recipients

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CRAD001AKR11T

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Chul-Woo Yang, MD [clinicaltrials_resource:469a8055b744dc7dfb8cb835bab91e8c]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

Korea: Food and Drug Administration [clinicaltrials_resource:ea25a7c46de176a17abdd13eb3d484b4]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:fa608ff6203cca5c8027db6a47392c17]

source [clinicaltrials_vocabulary:source]

Seoul St. Mary's Hospital [clinicaltrials_resource:3dd51fe21291c57b6fa19fca7c5200f8]

start date [clinicaltrials_vocabulary:start-date]

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02036554 study design [clinicaltrials_resource:d9fe749076a4547c6fc86fe79ec469a0]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02036554

verification date [clinicaltrials_vocabulary:verification-date]

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02036554

http://www.w3.org/2001/XMLSchema#string

title

Evaluate Efficacy Study of Com ...... in Renal Allograft Recipients

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Evaluate Efficacy Study of Com ...... s [clinicaltrials:NCT02036554]

@en